JUN 6·Zacks CommentaryMed
Wall Street Analysts Think Silence Therapeutics ( SLN ) Could Surge 556.19%: Read This Before Placing a Bet
The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.